# Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

> **NCT02201420** · PHASE2 · COMPLETED · sponsor: **Navidea Biopharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Kaposi's Sarcoma

## Interventions

- **DRUG:** Tc 99m tilmanocept

## Key facts

- **NCT ID:** NCT02201420
- **Lead sponsor:** Navidea Biopharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2015-03
- **Final completion:** 2015-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2016-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02201420

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02201420, "Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02201420. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*